xanthine oxidase-in-1

Xanthine oxidase-IN-1是一种有效的黄嘌呤氧化酶抑制剂(IC50值:6.5 nM),是一种利用核酸和核苷酸介质降解产生的生物活性核苷酸在嘌呤分解代谢中起核心作用的化合物，

Xanthine oxidase-IN-11 (XO8 analog) 是一种有效的黄嘌呤氧化酶 (XO) 抑制剂。

Xanthine oxidase-IN-12 (Compound 11), 作为一种高效的黄嘌呤氧化酶 (XO) 抑制剂，其IC50值达到91 nM。此外，Xanthine oxidase-IN-12 亦展现出抗氧化活性，能降低细胞内活性氧种 (ROS) 的水平。

Xanthine oxidase-IN-16 作为一款高效的黄嘌呤氧化酶 (xanthine oxidase(XO)) 抑制剂，展示了出色的口服活性和在 IC50 为 102 nM 的情况下的抑制效果。此化合物在治疗高尿酸血症大鼠方面显示了显著的疗效。

Xanthine oxidase-IN-10 (XO8 analog) 是一种黄嘌呤氧化酶 (XO) 抑制剂，可用于研究痛风。

Nicotinamide N-oxide (Nicotinamide 1-oxide) 是生物体内烟酰胺分解代谢物，是高效选择性CXCR2受体拮抗剂。

CYPMPO is a free radical spin trap with excellent trapping capabilities toward hydroxyl and superoxide radicals in biological and chemical systems. Decay of the superoxide adduct of CYPMPO proceeds in an apparent first order fashion with half-lives of 15 and 51 minutes in a UV-illuminated hydrogen peroxide solution and a hypoxanthine/xanthine oxidase system, respectively. CYPMPO traps superoxide radicals generated by bovine neutrophils as effectively as DEPMPO.[1] The high melting point (126°C), low hygroscopic properties, and long shelf-life in aqueous solutions offer significant practical advantages for use of CYPMPO over DEPMPO and DMPO.

Xanthine oxidase-IN-7 (compound1h) 是一种口服的黄嘌呤氧化酶(XO)抑制剂 (IC50 = 0.36 μM)。Xanthine oxidase-IN-7 可有效降低血清尿酸水平，在高尿酸血症和痛风的研究中具有潜力。

Xanthine oxidase-IN-4 (化合物 19a) 是一种具有口服活性的有效黄嘌呤氧化酶 (XO) 抑制剂，IC50值为0.039 μM，可用于高尿酸血症和痛风的研究。Xanthine oxidase-IN-4 在氧嗪酸钾诱导的高尿酸血症大鼠中表现出降尿酸能力。

Febuxostat (TEI 6720) sodium 在痛风和高尿酸血症研究中具有潜力，它是一种有效的、选择性的、非嘌呤的黄嘌呤氧化酶 (XO)抑制剂，Ki 值为 0.6 nM。

Xanthine oxidase-IN-5, a powerful and orally active inhibitor of xanthine oxidase (XO), exhibits an IC50 value of 0.70 μM. It possesses favorable drug-like characteristics, with ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Moreover, Xanthine oxidase-IN-5 showcases significant hypouricemic effects in a hyperuricemic rat model [1].

XO COX LOX-IN-1 是一种黄嘌呤氧化酶 环氧酶 脂氧合酶 XO COX LOX 的有效抑制剂。XO COX LOX-IN-1 能够用于研究炎症、癌症以及代谢性疾病。

Febuxostat 67M-1 is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat 67M-4 is a derivative compound of Febuxostat 67M-1 which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and reduces the risk of gout or kidney stone formation.

Febuxostat 67M-2 is a derivative compound of Febuxostat 67M-1 which is an inhibitor of xanthine oxidase. It reduces uric acid production in the body and also used to reduce the risk of gout or kidney stone formation.

6-Methoxypurine-9-β-D-5’(R)-C-methylriboside 是一种嘌呤碱基，属于次黄嘌呤似物，主要在肌肉组织中发现。作为黄嘌呤在嘌呤氧化酶作用下的代谢产物，次黄嘌呤具备显著的抗炎性质，并可作为内源性 poly(ADP-ribose) polymerase (PARP) 的抑制剂。其通过抑制 PARP 活性，防止过氧亚硝酸盐引起的线粒体去极化及次级超氧化物的产生，展现出细胞保护作用。同时，次黄嘌呤也被用作缺氧的生物标志物。

Xanthine oxidase-IN-8 (Icarisids J) (Compound 7) 是一种 XOD 抑制剂，IC50值为 29.71 μM。

Xanthine oxidase-IN-9 (Icarisids E) (Compound 2)，一种黄嘌呤氧化酶 (XOD) 高效抑制剂，具有31.81 μM 的 IC50 值。

NoxA1ds TFA is a potent and selective inhibitor of NADPH oxidase 1 (NOX1), with an inhibition concentration (IC50) of 20 nM, demonstrating selectivity over NOX2, NOX4, NOX5, and xanthine oxidase. It effectively inhibits NOX1-derived O2- production in HT-29 human colon cancer cells and attenuates VEGF-induced migration of human pulmonary artery endothelial cells under hypoxic conditions in vitro.

URAT1&XO inhibitor 1（化合物29）是一种对URAT1(IC50≈10μM)和黄嘌呤氧化酶(IC50=1.01μM)具有双重抑制作用的抑制剂。该化合物能够在氧酸钾引起的高尿酸血症大鼠模型中降低血尿酸水平，已广泛应用于高尿酸血症的研究。

URAT1&XO inhibitor 2 (Compound BDEO)是一种针对xanthine oxidase (黄嘌呤氧化酶) 及URAT1的双重抑制剂，对xanthine oxidase展现出优异的抑制效果，IC50值为3.3 μM。该化合物在表达URAT1的HEK293细胞中显著抑制尿酸的摄取，其Ki值达到0.145 μM。在动物模型中，URAT1&XO inhibitor 2有效降低高尿酸血症小鼠的血清尿酸水平，并增加尿酸的排泄。该化合物主要用于高尿酸血症的研究。

Potent and selective NADPH oxidase 1 (NOX1) inhibitor (IC50 = 20 nM). Exhibits selectivity for NOX1 over NOX2, NOX4, NOX5 and xanthine oxidase. Inhibits NOX1-derived O2- production in HT-29 human colon cancer cells. Attenuates VEGF-induced human pulmonary

NoxA1ds acetate(1435893-78-9 free base) 是一种有效的选择性 NADPH 氧化酶 1 (NOX1) 抑制剂 (IC50 : 20 nM)。对 NOX1 的选择性优于对 NOX2、NOX4、NOX5 和黄嘌呤氧化酶的选择性。它抑制 HT-29 人结肠癌细胞中 NOX1 衍生的 O2 产生。在体外缺氧条件下减弱 VEGF 诱导的人肺动脉内皮细胞迁移。